OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
OS Therapies IncorporatedAMEX: OSTX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $5.21M rose 394.9% year over year, ahead of the +3.6% change in trailing-twelve-month financing cash flow. Sequentially, it rose 145.4% from the prior quarter. Over 3 fiscal years it compounded at +1272.4% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +394.9% holds above the trailing-twelve-month pace of +3.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 9.44B USD
- Year-over-year change
- +73793.9%
- 4-year CAGR
- +645.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.44B | +73793.9% |
| FY2024 | 2024-12-31 | 12.78M | +344.7% |
| FY2023 | 2023-12-31 | 2.87M | -21.3% |
| FY2022 | 2022-12-31 | 3.65M | +19.7% |
| FY2021 | 2021-12-31 | 3.05M | — |
Financing Cash Flow vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 financing cash flow of $13.6M is the 6th largest of the 9 companies compared; the peer median is $15.87M.
- Its year-over-year change of +3.6% is the 6th highest of 8, against a peer median of +93.8%.
- Over three fiscal years its annual growth of +1272.4% compares with a peer median of -10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $65.68M | +25657.6% | — | — | |
| LTM Mar 2026 | $57.81M | +3300.9% | — | — | |
| LTM Mar 2026 | $47.24M | +93.8% | -8.9% | 14179.4% | |
| LTM Jun 2026 | $26.77M | -1014.0% | -27.6% | 127.5% | |
| LTM Mar 2026 | $19.12M | +27.6% | -10.3% | 833.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $13.6M | +3.6% | +1272.4% | — |
| LTM Mar 2026 | $12.62M | +97.5% | — | — | |
| LTM Mar 2026 | $8.35M | -18.6% | +35.8% | 590.3% | |
| LTM Jun 2024 | $2.15M | — | -37.1% | 264.1% | |
| Peer median (excluding OSTX) | $15.87M | +93.8% | -10.3% | 590.3% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75B) |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 268.3K | 4.27B |
| Change in Working Capital | 574.67K | 947.33K | 2.02M | (129.64K) | 9.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 856.48K | 216.43K | 1.35M | (1.05M) | 8.27M |
| Other Working Capital | (281.81K) | 730.9K | 669.65K | 923.69K | 834.81K |
| Other Non-Cash Items | 2.44M | 1.51M | 2.76M | 1.46M | 9.88B |
| Operating Cash Flow | (4.4M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
| Capital Expenditures | (11.93K) | 0 | 0 | 0 | (466.42K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 212.41K | 230.88K | 1.15K | 0 | (465.96M) |
| Investing Cash Flow | 200.47K | 230.88K | 1.15K | 0 | (466.42M) |
| Debt Repayment | 2.95M | 3.82M | 3.16M | 1.5M | 0 |
| Common Stock Issued | 0 | 0 | 0 | 5.23M | 8.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (31.25M) | 0 |
| Other Financing Activities | 100K | (172.02K) | (284.18K) | 31.25M | 9.43B |
| Financing Cash Flow | 3.05M | 3.65M | 2.87M | 12.78M | 9.44B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.15M) | 90.69K | (132.5K) | 5.49M | (5.26B) |
| Free Cash Flow | (4.41M) | (3.79M) | (3.01M) | (7.28M) | (14.24B) |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.